These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9764774)

  • 1. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine.
    De Boer RJ; Boucher CA; Perelson AS
    AIDS; 1998 Sep; 12(13):1567-70. PubMed ID: 9764774
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term suppression of HIV-1 by hydroxyurea and didanosine.
    Lori F; Jessen H; Foli A; Lisziewicz J; Matteo PS
    JAMA; 1997 May; 277(18):1437-8. PubMed ID: 9145714
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor.
    Lisziewicz J; Jessen H; Finzi D; Siliciano RF; Lori F
    Lancet; 1998 Jul; 352(9123):199-200. PubMed ID: 9683211
    [No Abstract]   [Full Text] [Related]  

  • 4. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.
    López M; Benito JM; Lozano S; Barreiro P; Martínez P; González-Lahoz J; Soriano V
    AIDS; 2004 Jun; 18(9):1251-61. PubMed ID: 15362657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?
    Colebunders R; Florence E; Ostyn B
    Int J Infect Dis; 2001; 5(4):234; author reply 234-5. PubMed ID: 11962349
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
    Lori F; Jessen H; Lieberman J; Clerici M; Tinelli C; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 May; 15(7):619-24. PubMed ID: 10331440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
    Lori F; Lisziewicz J
    Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Hydroxyurea for real?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
    Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
    Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
    J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.
    Vila J; Nugier F; Barguès G; Vallet T; Peyramond D; Hamedi-Sangsari F; Seigneurin JM
    Lancet; 1997 Aug; 350(9078):635-6. PubMed ID: 9288048
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine.
    Luzzati R; Di Perri G; Fendt D; Ramarli D; Broccali G; Concia E
    J Antimicrob Chemother; 1998 Oct; 42(4):565-6. PubMed ID: 9818769
    [No Abstract]   [Full Text] [Related]  

  • 13. Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy.
    Barreiro P; de Mendoza C; Soriano V; González-Lahoz J
    AIDS; 2000 Jan; 14(2):207-8. PubMed ID: 10708295
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.
    Foli A; Maserati R; Minoli L; Wainberg MA; Gallo RC; Lisziewicz J; Lori F
    AIDS; 1998 Jun; 12(9):1113-4. PubMed ID: 9662215
    [No Abstract]   [Full Text] [Related]  

  • 15. Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.
    Yerly S; Rutschmann OT; Opravil M; Marchal F; Hirschel B; Perrin L
    J Infect Dis; 1999 Sep; 180(3):850-3. PubMed ID: 10438378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?
    Sanne I; Smego RA; Mendelow BV
    Int J Infect Dis; 2001; 5(1):43-8. PubMed ID: 11285159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1.
    Paton NI; Aboulhab J; Karim F
    Lancet; 2002 May; 359(9318):1667-8. PubMed ID: 12020529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principles of treating HIV.
    Johnson D
    S Afr Med J; 2000 Mar; 90(3):227-30. PubMed ID: 10853393
    [No Abstract]   [Full Text] [Related]  

  • 19. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
    Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.
    Barreiro P; Soriano V; Valencia E; Díaz B; González-Lahoz J
    AIDS; 2001 Dec; 15(18):2469-70. PubMed ID: 11774839
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.